To Stay, or Not to Stay, on Natalizumab in MSTo Stay, or Not to Stay, on Natalizumab in MS

As PML risk is greatest after 2 years of taking natalizumab, patients may consider switching to another drug, but a new study suggests that those who do are at increased risk for disability progression. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news